Here's the one big worry a lot of investors have about Vertex Pharmaceuticals (NASDAQ: VRTX) these days: revenue prospects beyond its main cystic fibrosis (CF) business. Vertex is moving candidates through the pipeline in other areas such as blood disorders, pain, and a rare lung and liver disorder called alpha-1 antitrypsin deficiency. Of course, as a shareholder I'd like to see Vertex bring one or more of those potential products to market.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting